Amador DMB

Language: Spanish
References: 26
Page: 73-76
PDF size: 86.83 Kb.

Text Extraction

No abstract

REFERENCES

1. Annual Revie del Colegio de Medicina Interna de México. Enfoque clínico actual en medicina interna.1ª edición, 2005;1,7,129.

2. Physicians desk referente. Actualizacion en diabetes. Thompson PLM.2004;67-75.

3. Diabetes Prevention Program Research. Group. Diabetes Prevention Program trial.Diabetes Care 1999;22:623-634.

4. “Diabetes Prevention Program Research. Group Reduction in the incidence of the type 2 Diabetes whit lifestyle intervention or Metformin”. The New England Journal of Medicine. Vol. 346. No. 6. Febrero, 2002;393-402.

5. Sherwin, R.S. et al. “The prevention or delay of type 2 diabetes. Position statement of the American Diabetes Association and national institute of diabetes, digestive and kidney diseases”. Diabetes Care. 2002:vol.25 no.4:742-749.

6. Unwim. N. et al. “Impaired glucose tolerance and impaired fasting glycaemia.The current status on definition and intervention”. Diabetes medicine. 2002:Vol.19;9:708-723.

7. Kirpichnikov, D.; et al. “Metformin: An update”. Annals of interna Medicine. 2002;137:25-33.

8. Lehtovirta, M. et al. “Metabolic effects of Metformin in patients whit impaired glucose tolerance”. Diabetic Medicine. Vol. 18. 2001;578- 583.

9. Stephanie, M. Benjamín. et al. Diabetes Care 2003;4:5:212-213.

10. Rull, JA. “Definición, clasificación y diagnósticode la diabetes mellitus. Análisis de los criterios del grupo de datos de diabetes y de la Organización Mundial de la Salud”. En: Gómez-Pérez, JF.; Rull, JA.; editor. Tratado de diabetología. Instituto Nacional de la Nutrición Salvador Zubirán. México, 1997,173-90.

11. Rull, JA.; Zárate, A. “Páncreas”. En: Rull, JA.; Zárate, A. Introducción a la Endocrinología. Francisco Méndez Cervantes, editor. México 1977;179-241. 12

12. Charles, MA.; Fontbonne, Ch. et al. “Risk factors for NIDDM in white population París”. Prospective Study Diabetes 1991;40 796-9.

13. National Diabetes Data Group. “Clasification and diagnosis of diabetes mellitus and other categories of glucose intolerance”. Diabetes 1979;28:1039- 1057.

14. Eastman, R. “Undiagnose diabetes or impaired glucose tolerance and cardiovascular risk”. Diabetes Care 1997;(20)2:127-8.

15. Harris, M.; Flegal, K.; Cowie, C.; Eberhardt. M.; Goldstein, D.; Little, R.; Wiedmeyer, H.; Byrd- Holt, D. “Prevalence Diabetes, impaired fasting glucose and impaired glucose tolerance in U.S. Adults: The Third National Health Nutrition Examination Survey, 1988-1994. Diabetes Care, April 1998. Vol 2 (4):518-524.

16. Torres, A. y Gutiérrez Rubio, Herrera Gómez, L.E. Intolerancia a la glucosa. Nueva entidad patológica. 2005, 23-27.

17. Fisher, E.; Walker, E.; Bostrom. A.; Fischhof, B.; Hair-Joshu, S. “Behavioral science research in prevention of diabetes: status and opportunities”. Diabetes Care. 2002, vol 25(3):599-606.

18. Toumilheto, J.; Lindstron, J.; Eriksson, J.; Valle, T.; Hamalainen, H.; llanneParikka, P.; Keinanen- Kiukaanniemi, S. “Prevention of type 2 Diabetes Mellitus by changes in lifestyle among subjects with impaired glucose tolerance”. Eng J Med. 2001 vol.3 44 (18): 1343-1350.

19. Pallardo, L.F. et al. Diabetes Care.2003;26:2318- 2322

20. The Decode Study Group. “Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2 hour diagnostic criteria”. Arch Inter Med 2001; 161:349-405.

21. Muggeo, M. et al. “Fasting plasma glucose. Variability predicts 10 year survival of type 2 diabetic patients. The Verona Diabetes Study”. Diabetes Care 2000; 23(1):45-50.

22. Singer, DE. et al. “Association of HbA1c whit prevalent cardiovascular disease in the original cohort of the Framingham Heart Study”. Diabetes 1992;41(2):202-8.23

23. American Diabetes Association. “Postprandial blood glucose”. Diabetes Care 2001; 24(4):775-8.

24. Kevin, JW.; Clin, J. “The mystery and importance of diabetic atherosclerotic vascular diasease”. Endocrinol Metab 2002; 87(1):33-34.

25. Haffner, SM “The importance of hyperglicemiea in the nonfasting state to the development of cardiovascular disease”. Endocrine review 1998;19(5):583-92.

26. Gu, K.; Cowie, CC.; Harris, MI. “Diabetes and decline in heart disease mortality in US adult”. JAMA 1999; 281(14):1291-7.